{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:08:25Z","timestamp":1792642105908,"version":"4.5.0"},"reference-count":25,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T00:00:00Z","timestamp":1582588800000},"content-version":"unspecified","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2020,1,31]]},"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Reactivation of hepatitis B virus (HBV) replication is a well-recognised complication in patients receiving disease-modifying anti-rheumatic drugs (DMARDs) for rheumatoid arthritis (RA). Limited data exist on HBV reactivation among patients with RA treated with janus kinase (JAK) inhibitors. The objective of the current study was to assess HBV reactivation in clinical trials of baricitinib, an oral selective JAK1 and JAK2 inhibitor in RA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data were integrated from four completed Phase 3 trials and one ongoing long-term extension (data up to 1 April 2017) in patients na\u00efve to DMARDs or who had inadequate response (IR) to DMARDs including methotrexate (MTX)-IR and\/or other conventional synthetic DMARD (csDMARD)-IR, or tumour necrosis factor inhibitors-IR. Within the clinical programme, baricitinib-treated patients may have received concomitant csDMARDs including MTX, or previous treatment with active comparators including MTX or adalimumab + MTX. At screening, all patients were tested for HBV surface antigen (HBsAg), core antibody (HBcAb) and surface antibody (HBsAb). Patients were excluded if they had (1) HBsAg+, (2) HBcAb+\/HBsAb\u2212 (in Japan, could enrol if HBV DNA\u2212) or (3) HBsAb+ and\u2009HBV DNA+. HBV DNA monitoring, following randomisation in the originating Phase 3 studies, was performed in Japan for patients with HBcAb+ and\/or HBsAb+ at screening, and was later instituted globally for HBcAb+ patients in accordance with evolving guidance for HBV monitoring and management with immunomodulatory therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 2890 patients received at least one dose of baricitinib in Phase 3 (6993 patient-years exposure). Of 215 patients with baseline serology suggestive of prior HBV infection (HbcAb+) who received a post-baseline DNA test, 32 (14.9%) were HBV DNA+ at\u2009some point following treatment initiation; 8 of 215 patients (3.7%) had a single quantifiable result (\u226529\u2009IU\/mL). Of these eight patients, four met the definition of reactivation of HBV (HBV DNA level \u2265100\u2009IU\/mL); baricitinib was permanently discontinued in four patients, and temporarily interrupted in two patients. No patient developed clinical evidence of hepatitis and in five of eight patients, antiviral therapy was not used.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>HBV reactivation can occur among RA patients treated with DMARDs, including baricitinib, with prior HBV exposure. Our data suggest that such patients should be monitored for HBV DNA during treatment and might be treated safely with the use of antiviral therapy as needed. The risk of HBV reactivation in patients with HBsAg treated with baricitinib is unknown.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2019-001095","type":"journal-article","created":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T12:45:10Z","timestamp":1582634710000},"page":"e001095","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":75,"title":["Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis"],"prefix":"10.1136","volume":"6","clinical-trial-number":[{"clinical-trial-number":"nct01885078","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6418-2603","authenticated-orcid":false,"given":"Masayoshi","family":"Harigai","sequence":"first","affiliation":[{"name":"Institute of Rheumatology, Tokyo Women\u2019s Medical University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Winthrop","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Oregon Health and Science University, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Rheumatology, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9897-6957","authenticated-orcid":false,"given":"Tsu-Yi","family":"Hsieh","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ming","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef S","family":"Smolen","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7518-1131","authenticated-orcid":false,"given":"Gerd","family":"Burmester","sequence":"additional","affiliation":[{"name":"Rheumatology, Charit\u00e9 - University Medicine Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Walls","sequence":"additional","affiliation":[{"name":"Eli Lilly and Co, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Shuo","family":"Wu","sequence":"additional","affiliation":[{"name":"Eli Lilly and Co, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Dickson","sequence":"additional","affiliation":[{"name":"Eli Lilly and Co, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Liao","sequence":"additional","affiliation":[{"name":"Eli Lilly and Co, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5294-4503","authenticated-orcid":false,"given":"Mark C","family":"Genovese","sequence":"additional","affiliation":[{"name":"Division of Immunology and Rheumatology, Stanford University, Palo Alto, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,2,25]]},"reference":[{"key":"2025090312060575000_6.1.e001095.1","doi-asserted-by":"crossref","first-page":"344","DOI":"10.4254\/wjh.v7.i3.344","article-title":"Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: extending perspective from old to newer drugs","volume":"7","author":"Nard","year":"2015","journal-title":"World J Hepatol"},{"key":"2025090312060575000_6.1.e001095.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.04.003"},{"key":"2025090312060575000_6.1.e001095.3","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-015-9675-4"},{"key":"2025090312060575000_6.1.e001095.4","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a021410","article-title":"Hepatitis B virus epidemiology","volume":"5","author":"MacLachlan","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2025090312060575000_6.1.e001095.5","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2015.20.35.30009","article-title":"Hepatitis B virus, hepatitis C virus and human immunodeficiency virus infection in undocumented migrants and refugees in southern Italy, January 2012 to June 2013","volume":"20","author":"Coppola","year":"2015","journal-title":"Euro Surveill"},{"key":"2025090312060575000_6.1.e001095.6","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s00103-016-2333-8","article-title":"[Current seroprevalence, vaccination and predictive value of liver enzymes for hepatitis B among refugees in Germany]","volume":"59","author":"Hampel","year":"2016","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"2025090312060575000_6.1.e001095.7","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","article-title":"Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions","volume":"152","author":"Loomba","year":"2017","journal-title":"Gastroenterology"},{"key":"2025090312060575000_6.1.e001095.8","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3109\/s10165-011-0458-z","article-title":"Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and\/or nonbiological disease-modifying antirheumatic drugs","volume":"21","author":"Mori","year":"2011","journal-title":"Modern Rheumatology"},{"key":"2025090312060575000_6.1.e001095.9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jmii.2017.10.002","article-title":"Risk-Stratified management strategies for HBV reactivation in RA patients receiving biological and targeted therapy: a narrative review","volume":"52","author":"Chen","year":"2019","journal-title":"J Microbiol Immunol Infect"},{"key":"2025090312060575000_6.1.e001095.10","doi-asserted-by":"crossref","first-page":"171","DOI":"10.5606\/ArchRheumatol.2014.3822","article-title":"Acute hepatic failure caused by hepatitis B virus reactivation in patients receiving immunomodulatory agents for autoimmune diseases","volume":"29","author":"Hsu","year":"2014","journal-title":"Arch Rheumatol"},{"key":"2025090312060575000_6.1.e001095.11","doi-asserted-by":"crossref","DOI":"10.1038\/nrrheum.2017.51","article-title":"Erratum: the emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"2025090312060575000_6.1.e001095.12","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","article-title":"Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025090312060575000_6.1.e001095.13","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"2025090312060575000_6.1.e001095.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210094"},{"key":"2025090312060575000_6.1.e001095.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507247"},{"key":"2025090312060575000_6.1.e001095.16","unstructured":"Hepatitis B Foundation . Diagnosed with chronic hepatitis B? what does your HBV DNA test tell you? 2016. Available: http:\/\/www.hepb.org\/blog\/diagnosed-with-chronic-hepatitis-b-what-does-your-hbv-dna-test-tell-you\/ [Accessed 6 May 2019]."},{"key":"2025090312060575000_6.1.e001095.17","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.10.038"},{"key":"2025090312060575000_6.1.e001095.18","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.rdc.2016.09.012","article-title":"Hepatitis B reactivation in rheumatic diseases: screening and prevention","volume":"43","author":"Koutsianas","year":"2017","journal-title":"Rheum Dis Clin North Am"},{"key":"2025090312060575000_6.1.e001095.19","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20130"},{"key":"2025090312060575000_6.1.e001095.20","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.148783"},{"key":"2025090312060575000_6.1.e001095.21","first-page":"118","article-title":"Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy","volume":"31","author":"Lee","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312060575000_6.1.e001095.22","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/1756-185X.12359","article-title":"Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs","volume":"19","author":"Nakamura","year":"2016","journal-title":"Int J Rheum Dis"},{"key":"2025090312060575000_6.1.e001095.23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211322"},{"key":"2025090312060575000_6.1.e001095.24","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22945"},{"key":"2025090312060575000_6.1.e001095.25","doi-asserted-by":"crossref","first-page":"10274","DOI":"10.3748\/wjg.v21.i36.10274","article-title":"Hepatitis B virus reactivation associated with antirheumatic therapy: risk and prophylaxis recommendations","volume":"21","author":"Mori","year":"2015","journal-title":"WJG"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2019-001095","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:06:13Z","timestamp":1756926373000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2019-001095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,2,25]]},"published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.1136\/rmdopen-2019-001095"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2019-001095","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2]]}}}